Robert E. Gerszten
Impact in
- Cancer Research top 0.2%
- Cancer, Hypoxia, and Metabolism
- MicroRNA in disease regulation
-
- Chemotherapy-induced cardiotoxicity and mitigation
Papers in
-
- Metabolomics and Mass Spectrometry Studies 59
- Metabolism, Diabetes, and Cancer 8
- Physiology 45
- Adipose Tissue and Metabolism 22
- Diet and metabolism studies 20
- Co-authors
- Thomas J. Wang (42 shared papers)Clary B. Clish (39 shared papers)Gregory D. Lewis (19 shared papers)Eugene P. Rhee (19 shared papers)Ramachandran S. Vasan (24 shared papers)Ru Wei (2 shared papers)Martin G. Larson (17 shared papers)Matthew G. Vander Heiden (1 shared paper)
- Journals
- Circulation (18 papers)Journal of the American College of Cardiology (10 papers)Diabetes (9 papers)Circulation Research (9 papers)Journal of the American Heart Association (8 papers)
- Partner nations
- United StatesCanadaSweden
In The Last Decade
Robert E. Gerszten
230 papers receiving 23.2k citations
Robert E. Gerszten's Hit Papers
Peers
Comparison fields: 5 of 172
- Cancer Research 3.1k
- Cardiology and Cardiovascular Medicine 3.3k
- Molecular Biology 10.5k
- Physiology 3.6k
- Biological Psychiatry 300
Countries citing papers authored by Robert E. Gerszten
This map shows the geographic impact of Robert E. Gerszten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert E. Gerszten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert E. Gerszten more than expected).
Fields of papers citing papers by Robert E. Gerszten
This network shows the impact of papers produced by Robert E. Gerszten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert E. Gerszten. The network helps show where Robert E. Gerszten may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert E. Gerszten, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 241 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Metabolite profiles and the risk of developing diabetes Hit paper breakdown → | 2011 | 2370 |
| 2 | The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth Hit paper breakdown → | 2008 | 2271 |
| 3 | MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions Hit paper breakdown → | 1999 | 1041 |
| 4 | MicroRNA-33 and the SREBP Host Genes Cooperate to Control Cholesterol Homeostasis Hit paper breakdown → | 2010 | 788 |
| 5 | Growth Differentiation Factor 11 Is a Circulating Factor that Reverses Age-Related Cardiac Hypertrophy Hit paper breakdown → | 2013 | 710 |
| 6 | Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab Hit paper breakdown → | 2012 | 578 |
| 7 | Targeted Metabolomics Hit paper breakdown → | 2012 | 495 |
| 8 | Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans Hit paper breakdown → | 2011 | 487 |
| 9 | Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients Hit paper breakdown → | 2011 | 482 |
| 10 | 2012 | 462 | |
| 11 | Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in Patients With Breast Cancer Treated With Doxorubicin, Taxanes, and Trastuzumab Hit paper breakdown → | 2013 | 407 |
| 12 | Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension Hit paper breakdown → | 2007 | 394 |
| 13 | 2005 | 365 | |
| 14 | Circulating branched‐chain amino acid concentrations are associated with obesity and future insulin resistance in children and adolescents Hit paper breakdown → | 2012 | 355 |
| 15 | 2003 | 336 | |
| 16 | 2008 | 314 | |
| 17 | 2007 | 313 | |
| 18 | 2008 | 259 | |
| 19 | 2008 | 256 | |
| 20 | 2016 | 252 |
About Robert E. Gerszten
Robert E. Gerszten is a scholar working on Molecular Biology, Physiology, Cardiology and Cardiovascular Medicine, Epidemiology and Cancer Research, having authored 241 papers that have together received 23.5k indexed citations. Recurring topics across this work include Metabolomics and Mass Spectrometry Studies (59 papers), Adipose Tissue and Metabolism (22 papers), Diet and metabolism studies (20 papers), Advanced Proteomics Techniques and Applications (16 papers), Cell Adhesion Molecules Research (12 papers), Adipokines, Inflammation, and Metabolic Diseases (9 papers), Metabolism, Diabetes, and Cancer (8 papers) and Liver Disease Diagnosis and Treatment (8 papers). The work is most often cited by research in Cancer Research (3.1k citations), Cardiology and Cardiovascular Medicine (3.3k citations), Molecular Biology (10.5k citations), Physiology (3.6k citations) and Biological Psychiatry (300 citations). Robert E. Gerszten has collaborated with scholars based in United States, Canada and Sweden. Frequent co-authors include Thomas J. Wang, Clary B. Clish, Gregory D. Lewis, Eugene P. Rhee, Ramachandran S. Vasan, Ru Wei, Martin G. Larson, Matthew G. Vander Heiden, Stuart L. Schreiber and Arvind Ramanathan. Their work appears in journals such as Circulation, Journal of the American College of Cardiology, Diabetes, Circulation Research and Journal of the American Heart Association.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.